CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences. Presentations will consist of a panel discussion and a corporate overview.
31st Annual Cancer Progress Conference – May 5-6, 2020
Panel: Paradigm-shifting Platforms II, Non-IO: Targeting Better, Targeting the Intractable
Date: May 5, 2020
Time: 11:45 a.m. EDT
Bank of America Securities 2020 HealthCare Conference – May 12-14, 2020
Date: May 12, 2020
Time: 5:00 p.m. EDT
About Ribon Therapeutics
Ribon Therapeutics is a clinical-stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.